Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females

References

• Paz-BaileyGRamaswamyMHawkesSJGerettiAMHerpes simplex virus type 2: epidemiology and management options in developing countriesSex Transm Infect200783162217098770
   PubMed Web of Science ®Google Scholar
• MertzGJBenedettiJAshleyRSelkeSACoreyLRisk factors for the sexual transmission of genital herpesAnn Intern Med19921161972021309413
   PubMed Web of Science ®Google Scholar
• CoreyLAdamsHGBrownZAHolmesKKGenital herpes simplex virus infections: clinical manifestations, course, and complicationsAnn Intern Med1983989589726344712
   PubMed Web of Science ®Google Scholar
• KarimSSKarimQEffectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in womenAbstract TUSS0204 presented at the XVIII International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• Abdool KarimQAbdool KarimSSFrohlichJAEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenScience20103291168117420643915
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdfAccessed April 10, 2012
   Google Scholar
• ThompsonMAAbergJACahnPAntiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panelJAMA201030432133320639566
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical SocietyGuidelines: clinical management and treatment of HIV infected adults in Europe Available at: http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41Accessed June 2, 2012
   Google Scholar
• GazzardBGAndersonJBabikerABritish HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008HIV Med2008956360818826546
   PubMed Web of Science ®Google Scholar
• World Health OrganisationRapid advice: antiretroviral therapy for HIV infection in adults and adolescents Available at: http://www.who.int/hiv/pub/arv/advice/en/index.htmlAccessed July 2, 2012
   Google Scholar
• Van DammeLRamjeeGAlaryMEffectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trialLancet200236097197712383665
   PubMed Web of Science ®Google Scholar
• PetersonLNandaKOpokuBKSAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in GhanaPLoS One20072e131218091987
   PubMed Web of Science ®Google Scholar
• Skoler-KarpoffSRamjeeGAhmedKEfficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trialLancet20083721977198719059048
   PubMed Web of Science ®Google Scholar
• McCormackSRamjeeGKamaliAPRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trialLancet20103761329133720851460
   PubMed Web of Science ®Google Scholar
• Abdool KarimSSRichardsonBARamjeeGSafety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenAIDS20112595796621330907
   PubMed Web of Science ®Google Scholar
• MayerKHMaslankowskiLAGaiFSafety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected womenAIDS20062054355116470118
   PubMed Web of Science ®Google Scholar
• HillierSLJoshiSCyrus-CameronESafety and acceptability of coitally dependent use of 1% tenofovir gel over six months of useAbstract 655 presented at the Microbicides ConferenceFebruary 24–27, 2008New Delhi, India
   Google Scholar
• CranageMSharpeSHerreraCPrevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gelPLoS Med20085e15718684007
   PubMed Web of Science ®Google Scholar
• ParikhUMDobardCSharmaSComplete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabineJ Virol200983103581036519656878
   PubMed Web of Science ®Google Scholar
• RohanLCMonclaBJKunjara Na AyudhyaRPIn vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicidePLoS One20105e931020174579
   PubMed Web of Science ®Google Scholar
• CheshenkoNKellerMJMasCasulloVCandidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spreadAntimicrob Agents Chemother2004482025203615155195
   PubMed Web of Science ®Google Scholar
• ZacharopoulosVRPhillipsDMVaginal formulations of carrageenan protect mice from herpes simplex virus infectionClin Diagn Lab Immunol199744654689220165
   PubMedGoogle Scholar
• MaguireRABergmanNPhillipsDMComparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilizationSex Transm Dis20012825926511354263
   PubMed Web of Science ®Google Scholar
• ZeitlinLHoenTEAchillesSLTests of Buffergel for contraception and prevention of sexually transmitted diseases in animal modelsSex Transm Dis20012841742311460027
   PubMed Web of Science ®Google Scholar
• KellerMJZerhouni-LayachiBCheshenkoNPRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trialJ Infect Dis2006193273516323128
   PubMed Web of Science ®Google Scholar
• BalzariniJHolyAJindrichJDifferential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurineAntimicrob Agents Chemother1993373323388452366
   PubMed Web of Science ®Google Scholar
• De ClercqEThe acyclic nucleoside phosphonates from inception to clinical use: historical perspectiveAntiviral Res20077511317116336
   PubMed Web of Science ®Google Scholar
• AndreiGLiscoAVanpouilleCTopical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replicationCell Host Microbe20111037938922018238
   PubMed Web of Science ®Google Scholar
• TanDHKaulRRaboudJMWalmsleySLNo impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adultsAIDS20112520721021150556
   PubMed Web of Science ®Google Scholar
• GrantRMLamaJRAndersonPLPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med20103632587259921091279
   PubMed Web of Science ®Google Scholar
• LamaJMayerKSchechterMOral TDF and its impact in HSV-2 acquisition and clinical expressionAbstract 1003 presented at the 18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 2, 2011Boston, MA
   Google Scholar
• KashubaADAbdool KarimSSKraftEDo systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trialAbstract TUSS0503 presented at the XVIII International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• PattersonKBPrinceHAKraftEPenetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmissionSci Transl Med20113112114
   Web of Science ®Google Scholar
• DumondJBYehRFPattersonKBAntiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisAIDS2007211899190717721097
   PubMed Web of Science ®Google Scholar
• KwaraADelongARezkNAntiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapyClin Infect Dis20084671972518220480
   PubMed Web of Science ®Google Scholar
• SchwartzJLRountreeWKashubaADA multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gelPLoS One20116e2597422039430
   PubMed Web of Science ®Google Scholar
• SiberryGKWilliamsPLMendezHSafety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infantsAIDS2012261151115922382151
   PubMed Web of Science ®Google Scholar
• JohnstonCMagaretASelkeSRemingtonMCoreyLWaldAHerpes simplex virus viremia during primary genital infectionJ Infect Dis2008198313418471083
   PubMed Web of Science ®Google Scholar
• BrownZASelkeSZehJThe acquisition of herpes simplex virus during pregnancyN Engl J Med19973375095159262493
   PubMed Web of Science ®Google Scholar
• WaldALinkKRisk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysisJ Infect Dis2002185455211756980
   PubMed Web of Science ®Google Scholar
• ReynoldsSJRisbudARShepherdMERecent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in IndiaJ Infect Dis20031871513152112721931
   PubMed Web of Science ®Google Scholar
• FreemanEEWeissHAGlynnJRCrossPLWhitworthJAHayesRJHerpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studiesAIDS200620738316327322
   PubMed Web of Science ®Google Scholar
• MarkKEWaldAMagaretASRapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adultsJ Infect Dis20081981141114918783315
   PubMed Web of Science ®Google Scholar
• MarkKEWaldAMagaretASRapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adultsJ Acquir Immune Defic Syndr20105448248820616743
   PubMed Web of Science ®Google Scholar
• SchifferJTAbu-RaddadLMarkKEFrequent release of low amounts of herpes simplex virus from neurons: results of a mathematical modelSci Transl Med200917ra16
   PubMed Web of Science ®Google Scholar
• JohnstonCSaracinoMKuntzSStandard-dose and highdose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trialsLancet201237964164722225814
   PubMed Web of Science ®Google Scholar
• CunninghamALTurnerRRMillerACParaMFMeriganTCEvolution of recurrent herpes simplex lesions. An immunohistologic studyJ Clin Invest1985752262333880773
   PubMed Web of Science ®Google Scholar
• KoelleDMAbboHPeckAZiegweidKCoreyLDirect recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesionsJ Infect Dis19941699569618169426
   PubMed Web of Science ®Google Scholar
• KoelleDMCoreyLBurkeRLAntigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesionsJ Virol199468280328107512152
   PubMed Web of Science ®Google Scholar
• BoilyMCDimitrovDMâsseBHow much of the overall microbicide effectiveness against HIV is due to the protection of TFV gel against HSV-2 The CAPRISA-004 trialAbstract 999 presented at the 18th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2011Boston, MA
   Google Scholar
• GuptaRWarrenTWaldAGenital herpesLancet20083702127213718156035
   PubMed Web of Science ®Google Scholar
• AugenbraunMFeldmanJChirgwinKIncreased genital shedding of herpes simplex virus type 2 in HIV-seropositive womenAnn Intern Med19951238458477486467
   PubMed Web of Science ®Google Scholar
• BagdadesEKPillayDSquireSBO’NeilCJohnsonMAGriffithsPDRelationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infectionAIDS19926131713201361745
   PubMed Web of Science ®Google Scholar
• SafrinSAshleyRHoulihanCCusickPSMillsJClinical and serologic features of herpes simplex virus infection in patients with AIDSAIDS19915110711101657040
   PubMed Web of Science ®Google Scholar
• SiegalFPLopezCHammerGSSevere acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesionsN Engl J Med1981305143914446272110
   PubMed Web of Science ®Google Scholar
• YudinMHKaulRProgressive hypertrophic genital herpes in an HIVinfected woman despite immune recovery on antiretroviral therapyInfect Dis Obstet Gynecol2008200859253218784844
   PubMedGoogle Scholar
• HolmesAMcMenaminMMulcahyFBerginCThalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individualsClin Infect Dis200744e96e9917479932
   PubMed Web of Science ®Google Scholar
• BaconTHLevinMJLearyJJSariskyRTSuttonDHerpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapyClin Microbiol Rev20031611412812525428
   PubMed Web of Science ®Google Scholar
• ShethPMSunderjiSShinLYCoinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activationJ Infect Dis20081971394140118444797
   PubMed Web of Science ®Google Scholar
• KaulRPettengellCShethPMThe genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmissionJ Reprod Immunol200877324017395270
   PubMed Web of Science ®Google Scholar
• GrayRHLiXWawerMJDeterminants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, UgandaJ Infect Dis2004181209121515031789
   PubMed Web of Science ®Google Scholar
• TanDHSMurphyKShahPSWalmsleySLSystematic review of the impact of herpes simplex virus type 2 on HIV disease progressionAbstract 305 presented at the Ontario HIV Treatment Network Research ConferenceNovember 14–15, 2011Toronto, Canada
   Google Scholar
• LingappaJRBaetenJMWaldADaily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trialLancet201037582483320153888
   PubMed Web of Science ®Google Scholar
• ReynoldsSJMakumbiFNewellKEffect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trialLancet Infect Dis20121244144822433279
   PubMed Web of Science ®Google Scholar
• McMahonMASilicianoJDLaiJThe antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutationJ Biol Chem2008283312893129318818198
   PubMed Web of Science ®Google Scholar
• LiscoAVanpouilleCTchesnokovEPAcyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissuesCell Host Microbe2008426027018779052
   PubMed Web of Science ®Google Scholar
• CoreyLWaldACelumCLQuinnTCThe effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemicsJ Acquir Immune Defic Syndr20043543544515021308
   PubMed Web of Science ®Google Scholar
• GrayRHWawerMJBrookmeyerRProbability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, UgandaLancet20013571149115311323041
   PubMed Web of Science ®Google Scholar
• MalcolmRKEdwardsKLKiserPRomanoJSmithTJAdvances in microbicide vaginal ringsAntiviral Res201088Suppl 1S30S3921109066
   PubMed Web of Science ®Google Scholar
• JohnsonTJGuptaKMFabianJAlbrightTHKiserPFSegmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovirEur J Pharm Sci20103920321219958831
   PubMed Web of Science ®Google Scholar
• FriendDRDrug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmissionExpert Opin Drug Deliv2012941742722385316
   PubMed Web of Science ®Google Scholar
• BlishCABaetenJMHormonal contraception and HIV-1 transmissionAm J Reprod Immunol20116530230721087338
   PubMed Web of Science ®Google Scholar
• KellyLCarrDClarkMRIn vivo release in sheep of a dual loaded microbicide polyurethane vaginal ringPaper presented at the American Association of Pharmaceutical Scientists Annual Meeting and ExpositionOctober 23–27, 2011Washington, DC
   Google Scholar
• MossJAMaloneAMSmithTJSimultaneous delivery of tenofovir and acyclovir via an intravaginal ringAntimicrob Agents Chemother20125687588222123689
   PubMed Web of Science ®Google Scholar
• ZhangTSturgisTFYouanBBpH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmissionEur J Pharm Biopharm20117952653621736940
   PubMed Web of Science ®Google Scholar
• AlukdaDSturgisTYouanBBFormulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV preventionJ Pharm Sci20111003345335621437910
   PubMed Web of Science ®Google Scholar
• HamASUgaonkarSRShiLDevelopment of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infectionJ Pharm Sci20121011423143522227864
   PubMed Web of Science ®Google Scholar
• KiserPFMahalingamAFabianJDesign of tenofovir-UC781 combination microbicide vaginal gelsJ Pharm Sci20121011852186422359356
   PubMed Web of Science ®Google Scholar
• AndersonPLKiserJJGardnerEMRowerJEMeditzAGrantRMPharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionJ Antimicrob Chemother20116624025021118913
   PubMed Web of Science ®Google Scholar
• MossJABaumMMMaloneAMTenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal ringsAIDS20122670771022210639
   PubMed Web of Science ®Google Scholar
• MesquitaPMRastogiRSegarraTJIntravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infectionJ Antimicrob Chemother20126771730173822467632
   PubMed Web of Science ®Google Scholar
• RuanePDeJesusEBergerDGS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir disoproxil fumarate 300 mg in a 10-day monotherapy study of HIV-1+ patientsAbstract 103 presented at the 19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• AntonPCranstonRCarballo-DieguezARMP-02/MTN-006: A phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDFAbstract 34 LB presented at the 18th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2011Boston, MA
   Google Scholar
• McGowanIHoesleyCAndrewPMTN-007: a Phase 1 randomized, double-blind, placebo-controlled rectal safety and acceptability study of tenofovir 1% gelAbstract 34LB presented at the19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• FischerWHuntGSibekoSTenofovir resistance mutation frequencies assessed by deep pyrosequencing of plasma virus from breakthrough HIV infections: CAPRISA 004 microbicide trialAbstract 1063 presented at the 19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• WeiXMorrisLNaranbhaiVSensitive tenofovir resistance screening of HIV-1 from the genital tract of women with breakthrough infections: CAPRISA 004 tenofovir gel trialAbstract 33 presented at the 19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• TanDHKaulRWalsmleySLeft out but not forgotten: should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV?Can J Infect Dis Med Microbiol200920e1e720190881
   PubMedGoogle Scholar